Financial Summary $ in millions, except EPS amounts Second Quarter 2023 2022 Change Change Ex- Exchange Sales $15,035 $14,593 3% 7% GAAP net (loss) income1 (5,975) 3,944 **N/M N/M Non-GAAP net (loss) income that excludes certain items1,2* (5,220) 4,743 N/...
This Merck KGaA 2023 business report presents the course of business throughout the respective business year. The report complies with the disclosure requirement for corporate entities and generally includes the balance sheet, the annual statement of the
Not defined by International Financial Reporting Standards (IFRS). In fiscal 2023, the Merck Group generated net sales of € 20,993 million (2022: € 22,232 million), representing a year-on-year decline of € 1,239 million or -5.6%. Negative exchange rate effects served to...
2nd quarter at a glance Report & Documents Conference Calls Related News Key facts and Forecast Financial results of Q2 2023 Net sales decrease organically by −1.1% to € 5.3 billion EBITDA pre down organically by −7.0% to € 1.6 billion Healthcare business sector increases net sales ...
The forecast does not reflect any financial impact from Merck’s proposedacquisitionof biotech company Prometheus Biosciences earlier this month, the company noted. Merck said that deal is expected to close in the third quarter of 2023. Merck’sCovidtreatment molnupiravir first entered the market ...
First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines.
1Q24 Other Financial Disclosures (Excel) 1Q24 Prepared Remarks Q2 Created with Sketch.Webcast 2Q24 Merck Earnings Presentation 2Q24 Merck Earnings Announcement 2Q24 Merck Other Financial Disclosures Transcript Form 10-Q 2Q24 Other Financial Disclosures (Excel) ...
Q4 FY 2023 Online Report Annual Report (PDF) Single Entity Report Merck KGaA, Darmstadt, Germany Online Sustainability Report 2023 incl. SASB and TCFD report Sustainability Report (PDF) 2023 incl. SASB – TCFD Earnings Presentation Financial Statement (XLS) Financial Statement (PDF) Regional Sector...
After a busy few weeks of news about Merck‘s cancer-drug pipeline, the pharmaceutical company will announce its quarterly financial results on Thursday. Merck shares were down 6.6% so far this year as of Wednesday afternoon, amid a broader slide in pharmaceutical stocks triggered by regulatory ...
December 8, 2024 Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma